EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study

Mariana Diz Lopes iD, Francesco Pollastri, Francesca Mastropaolo, Rosanna Somma, Mattia Tugnolli, Emma Pasetto, Camilla Benini, Valeria Messina, Davide Gatti, Ombretta Viapiana, Maurizio Rossini, Elena Marchetti und 2 weitere

JBMR Plus · 03.09.2025 · 9 (10)

DOI: 10.1093/jbmrpl/ziaf144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JBMR Plus, online erschienen am 30.08.2025. Verfasst von Mariana Diz Lopes und 13 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Section, Department of Medicine, University of Verona, Verona 37134, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bone damage occurs early in the progression of plasma cell disorders. Romosozumab (ROMO), a sclerostin inhibitor with both anabolic and antiresorptive effects, may provide therapeutic benefit for this fracture-prone population. We conducted a 12-mo prospective observational study on postmenopausal women with osteoporosis and multiple myeloma (MM) treated with monthly ROMO. BMD was assessed at baseline, 6, and 12 mo with DXA and HR-pQCT. Additionally, bone turnover markers (BTMs) and several MM markers were also monitored. Eight female patients with MM without evidence of CRAB completed 12 mo of ROMO. A significant BMD increase was observed at the LS (+5.8%, p = .048), FN (+4.2%, p = .020), and TH (+3.3%, p = .002). Procollagen I intact N-terminal peptide rose sharply at month 3 (+117.8%) and returned to baseline by month 12 (p = .006). C-terminal telopeptide of type I collagen decreased progressively, showing a trend toward significance (−53.6%, p = .060). Alkaline phosphatase and bone alkaline phosphatase significantly declined by month 12 (p = .020 and p = .022). No significant changes occurred in immunoglobulins, M-protein, or light chains. β2-microglobulin decreased at month 12 (from 2.35 to 2.1 mg/L, p = .042), but the overall trend was not significant (p = .092). Failure load increased at month 6 (p = .033), while the other HR-pQCT parameters remained stable throughout the study. In this exploratory study of postmenopausal women with MM and osteoporosis, ROMO significantly improved BMD and modulated BTMs, without any evidence of disease progression over the 12-mo period. These findings support ROMO as a potential bone-targeted therapy in patients with osteoporosis and MM.

Schlagwörter

Stichwörter der Autor:innen

BMDbone turnover markersmultiple myelomaosteoporosisromosozumab

Autor:innen und Institutionen

  • Rheumatology Section, Department of Medicine, University of Verona, Verona 37134, Italy.
  • Rheumatology Department, Unidade Local de Saúde de São João, Porto 4200-319 Portugal.
  • Hematology Section, Department of Medicine, University of Verona, Verona 37134, Italy.

ORCID-Profile: Mariana Diz Lopes

Zitieren

APA

Lopes, M. D., Pollastri, F., Mastropaolo, F., Somma, R., Tugnolli, M., Pasetto, E., Benini, C., Messina, V., Gatti, D., Viapiana, O., Rossini, M., Marchetti, E., Tinelli, M., & Adami, G. (2025). Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study. JBMR Plus, 9(10). https://doi.org/10.1093/jbmrpl/ziaf144

Vancouver

Lopes MD, Pollastri F, Mastropaolo F, Somma R, Tugnolli M, Pasetto E, et al. Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study. JBMR Plus. 2025;9(10). doi:10.1093/jbmrpl/ziaf144

BibTeX
@article{Lopes2025,
  author = {Lopes, Mariana Diz and Pollastri, Francesco and Mastropaolo, Francesca and Somma, Rosanna and Tugnolli, Mattia and Pasetto, Emma and Benini, Camilla and Messina, Valeria and Gatti, Davide and Viapiana, Ombretta and Rossini, Maurizio and Marchetti, Elena and Tinelli, Martina and Adami, Giovanni},
  title = {Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study},
  journal = {JBMR Plus},
  year = {2025},
  volume = {9},
  number = {10},
  doi = {10.1093/jbmrpl/ziaf144}
}
Kostenlos starten →